Payment overview · 2025
General Payments
$263.54
13 reported records · 5 companies
Healthcare provider profile · identity verified
Suzanne Heidi Sample Staudinger, MD
Allopathic & Osteopathic Physicians|Family Medicine · BENTON CITY, WA · NPI 1861572737
Verified facts
What the public records show
CMS Open Payments records show Suzanne Heidi Sample Staudinger, MD received $263.54 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.35 | 31.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.00 | 30.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.82 | 17.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $29.57 | 11.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.80 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $263.54 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.00 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.00 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.53 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.53 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.82 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 271 | 42 |
| Lisinopril | Lisinopril | 257 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 38 |
| Omeprazole | Omeprazole | 176 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 49 |
| Losartan Potassium | Losartan Potassium | 155 | 47 |
| Metformin Hcl | Metformin Hcl | 154 | 40 |
| Trazodone Hcl | Trazodone Hcl | 148 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 30 |
| Gabapentin | Gabapentin | 123 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 24 |
| Ozempic | Semaglutide | 106 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 29 |
| Metformin Hcl Er | Metformin Hcl | 81 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 17 |
| Simvastatin | Simvastatin | 57 | 17 |
| Lovastatin | Lovastatin | 55 | 16 |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Potassium Chloride | Potassium Chloride | 54 | 22 |
| Jardiance | Empagliflozin | 53 | 14 |
| Eliquis | Apixaban | 51 | 13 |
| Alprazolam | Alprazolam | 50 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Furosemide | Furosemide | 50 | 20 |
| Allopurinol | Allopurinol | 49 | 14 |
| Tramadol Hcl | Tramadol Hcl | 45 | 12 |
| Ondansetron Odt | Ondansetron | 42 | suppressed |
| Carvedilol | Carvedilol | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 12 |
| Chlorthalidone | Chlorthalidone | 40 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 15 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $263.54 · 13 records | PFIZER INC. | INJECTAFER, JARDIANCE, NURTEC ODT, PAXLOVID, QULIPTA, REXULTI, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error